A unique combination of multiple sugars that independently paired with inositol has potential to inhibit the inflammatory and metabolic response of sugar alone
Caloric intake and glycemic index studies planned to support commercial label development
Patent issued in the United States and composition allowed in Japan and Russia.
Approved
Patents pending in European Union and China.
Pending
“Low Glycemic Sugar Composition” patent issued in the United States.
Approved
Maintaining a healthy diet is critical for human health and wellness. Laetose can reduce the glycemic index in foods by reducing sugar and calorie content, offering a valuable alternative in the U.S., where over $140 billion of sugar is consumed annually annually through food and beverages (U.S. Sugar Alliance). With diabetes a global concern and billions spent annually on treatment, Laetose shows the potential to inhibit tumor necrosis factor alpha, making it a promising candidate for pharmaceuticals to slow disease progression.
Laetose is immediately available for partnering and out-licensing. Please contact us to be a part of our story.
Get the latest news delivered to your inbox
